Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 27;5(11):e369.
doi: 10.1038/bcj.2015.94.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

T Barbui  1   2 , A M Vannucchi  3 , V Buxhofer-Ausch  4 , V De Stefano  5 , S Betti  5 , A Rambaldi  2 , E Rumi  6 , M Ruggeri  7 , F Rodeghiero  7 , M L Randi  8 , I Bertozzi  8 , H Gisslinger  4 , G Finazzi  2 , A Carobbio  1 , J Thiele  9 , F Passamonti  10 , C Falcone  1 , A Tefferi  11
Affiliations

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia

T Barbui et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Thrombosis-free survival in conventionally defined low- and high-risk (a and b) and in the revised risk classification (c and d). (a) Low-risk patients with or without additional risk factors (CV risk factors and JAK2 mutation); (b) High-risk patients with or without additional risk factors (CV risk factors and JAK2 mutation); (c) ‘Very low risk' (no thrombosis history, age ⩽60 years and JAK2-unmutated); ‘Low risk' (no thrombosis history, age ⩽60 years and JAK2-mutated); (d) ‘Intermediate risk' (no thrombosis history, age >60 years and JAK2-unmutated); ‘High risk' (thrombosis history or age >60 years with JAK2 mutation).
See this image and copyright information in PMC

References

    1. 1Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761–770. - PMC - PubMed
    1. 2Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood 2012; 120: 5128–5133. - PubMed
    1. 3Finazzi G, Carobbio A, Guglielmelli P. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood 2014; 124: 2611–2612. - PubMed
    1. 4Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 114: 937–951. - PubMed
    1. 5Alvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda JC et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood 2010; 116: 1205–1210. - PubMed

Publication types